Literature DB >> 18367025

Hypertension and kidney disease: a deadly connection.

Yousri M Barri1.   

Abstract

Kidney disease may be the cause or a consequence of hypertension. Hypertension affects 25% of the adult population in the United States. Similarly, chronic kidney disease (CKD) and end-stage renal disease (ESRD) have been steadily increasing in incidence because of the increasing age of the US population and rise in the incidence of risk factors, including hypertension. Substantial evidence supports the notion that elevated blood pressure is the most significant risk factor for developing CKD. Microalbuminuria has been shown to be the early marker of hypertensive renal disease. Furthermore, therapy to reduce microalbuminuria was associated with delayed progression of renal disease. Black Americans are at higher risk for developing hypertensive nephrosclerosis than whites. Hypertension is a major risk factor for cardiovascular events in patients with CKD and ESRD and those who have undergone renal transplantation. Studies have documented that elevated serum creatinine and CKD are risk factors for a cardiovascular event. Tight blood pressure control has been shown to reduce microalbuminuria and proteinuria and to delay progression of renal disease. Tailoring antihypertensive medication to the clinical setting to achieve a blood pressure goal is critical in reducing complications from this deadly connection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367025     DOI: 10.1007/s11906-008-0009-y

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  39 in total

1.  Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

Authors:  Kasper Rossing; Per K Christensen; Berit R Jensen; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

Review 2.  Diabetes, hypertension, and cardiovascular disease: an update.

Authors:  J R Sowers; M Epstein; E D Frohlich
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

3.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

4.  Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Authors:  Peter Jacobsen; Steen Andersen; Kasper Rossing; Berit R Jensen; Hans-Henrik Parving
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

Review 5.  The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease.

Authors:  Matthew R Weir
Journal:  Am J Hypertens       Date:  2005-04       Impact factor: 2.689

6.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Early predictors of 15-year end-stage renal disease in hypertensive patients.

Authors:  H M Perry; J P Miller; J R Fornoff; J D Baty; M P Sambhi; G Rutan; D W Moskowitz; S E Carmody
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

9.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group.

Authors:  N B Shulman; C E Ford; W D Hall; M D Blaufox; D Simon; H G Langford; K A Schneider
Journal:  Hypertension       Date:  1989-05       Impact factor: 10.190

10.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

View more
  25 in total

1.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

2.  Rosuvastatin beneficially alters the glomerular structure of kidneys from spontaneously hypertensive rats (SHRs).

Authors:  Erica Peres de Barros; Angélica Beatriz Garcia-Pinto; Priscilla Yório Machado; Mário José dos Santos Pereira; Jorge José de Carvalho
Journal:  J Mol Histol       Date:  2011-06-14       Impact factor: 2.611

3.  Accumulation of visceral fat in maintenance hemodialysis patients.

Authors:  Takatomi Yurugi; Satoshi Morimoto; Takayuki Okamoto; Yoshifumi Amari; Yuko Kasuno; Masayoshi Fukui; Fumitaka Nakajima; Mitsushige Nishikawa; Toshiji Iwasaka
Journal:  Clin Exp Nephrol       Date:  2011-10-13       Impact factor: 2.801

Review 4.  Epoxyeicosatrienoic acids, hypertension, and kidney injury.

Authors:  John D Imig
Journal:  Hypertension       Date:  2015-01-12       Impact factor: 10.190

Review 5.  Epoxyeicosanoids in hypertension.

Authors:  J D Imig
Journal:  Physiol Res       Date:  2019-09-02       Impact factor: 1.881

6.  Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice.

Authors:  Chao-Sheng Lo; Fang Liu; Yixuan Shi; Hasna Maachi; Isabelle Chenier; Nicolas Godin; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-28

Review 7.  Orally Active Epoxyeicosatrienoic Acid Analogs.

Authors:  William B Campbell; John D Imig; James M Schmitz; John R Falck
Journal:  J Cardiovasc Pharmacol       Date:  2017-10       Impact factor: 3.105

8.  Decreased NKCC1 activity in erythrocytes from African Americans with hypertension and dyslipidemia.

Authors:  Sergei N Orlov; Francis Gossard; Zdenka Pausova; Olga A Akimova; Johanne Tremblay; Clarence E Grim; Jane M Kotchen; Theodore A Kotchen; Daniel Gaudet; Allen W Cowley; Pavel Hamet
Journal:  Am J Hypertens       Date:  2009-12-31       Impact factor: 2.689

9.  Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension.

Authors:  Marlina Manhiani; Jeffrey E Quigley; Sarah F Knight; Shiva Tasoobshirazi; TarRhonda Moore; Michael W Brands; Bruce D Hammock; John D Imig
Journal:  Am J Physiol Renal Physiol       Date:  2009-06-24

10.  Prevalence and correlates of chronic kidney disease in a group of patients with hypertension in the Savanah zone of Cameroon: a cross-sectional study in Sub-Saharan Africa.

Authors:  Ba Hamadou; Jérôme Boombhi; Félicité Kamdem; Adeline Fitame; Sylvie Ndongo Amougou; Liliane Kuate Mfeukeu; Chris Nadège Nganou; Alain Menanga; Gloria Ashuntantang
Journal:  Cardiovasc Diagn Ther       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.